Alenson Carman 4
4 · AGIOS PHARMACEUTICALS, INC. · Filed Jun 23, 2021
Insider Transaction Report
Form 4
Alenson Carman
Principal Accounting Officer
Transactions
- Exercise/Conversion
Common stock
2021-06-21$51.51/sh+1,777$91,533→ 1,777 total - Sale
Common stock
2021-06-21$61.61/sh−1,777$109,481→ 0 total - Exercise/Conversion
Stock option (right to buy)
2021-06-21−1,777→ 3,555 totalExercise: $51.51Exp: 2030-02-14→ Common stock (1,777 underlying)
Footnotes (3)
- [F1]This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F3]This option was granted on February 14, 2020. The shares underlying this option vest as to 25% of the underlying shares on February 14, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.